市場調查報告書
商品編碼
1601596
胞磷膽鹼的全球市場:產品·用途·年齡層·流通管道·不同地區的預測 (~2032年)Global Citicoline Market Research Report Information by Product by Application, by Age Group by Distribution Channel, by Region Forecast till 2032 |
胞二磷膽鹼市場規模將從2023年的4.3億美元和2024年的4.8億美元增長到2032年的10.4億美元,預計在預測期內複合年增長率將達到8.99%。
由於健身和運動領域的需求不斷增加、認知健康意識的增強以及世界各地對臉部美容的渴望不斷增長,市場正在不斷擴大。
人口老化、認知增強的需求、神經系統疾病的增加是推動市場擴張的主要因素。近年來,大眾對在整個生命週期中維持大腦健康和認知功能重要性的理解發生了顯著變化。推動這一變化的因素有很多,包括資訊可用性的增加、老年人口的增加以及對認知能力下降和阿茲海默症等神經系統疾病的日益擔憂。
區域展望
2022年北美地區佔最大市場佔有率。這是由於北美老年人口不斷增加,臉部矯正和增強手術越來越普遍,人均可支配收入明顯更高。
由於該地區完善的製藥和醫療基礎設施以及人口老化,歐洲也佔據第二大市場佔有率。西班牙預計將在歐洲地區成長最快,而德國預計將擁有最大的市場佔有率。
從 2024 年到 2032 年,亞太地區預計將大幅擴張。這是亞太地區對認知健康越來越了解並了解胞二磷膽鹼補充劑可以提供的好處的結果。印度預計將成為該地區成長最快的國家,而中國預計將佔據最大的市場佔有率。
本報告提供全球胞磷膽鹼的市場調查,彙整市場定義和概要,市場成長的各種影響因素分析,市場規模的轉變·預測,各種區分·地區/各主要國家的明細,競爭環境,主要企業簡介等資訊。
Global Citicoline Market Research Report Information by Product (Capsules, Tablets, Powder, Eye Drops, and Injection) by Application (Sports Nutrition, Personal Wellness, Treatment [Glaucoma, Stroke, Alzheimer disease, Channel (pression, and Others]), by Age Group (Pediatric, Adult, and Geriatric) by Distribution Channel (Online Channel, Offline Channel), by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032
The size of the Citicoline market was estimated at USD 0.43 billion in 2023 and is expected to increase at a compound annual growth rate (CAGR) of 8.99% from 2024 to 2032, from USD 0.48 billion in 2024 to USD 1.04 billion by 2032. The market is expanding due to the growing demand from the fitness and sports sectors, the growing awareness of cognitive health, and the growing desire for facial aesthetics worldwide.
According to the report, the aging population, the need for cognitive enhancement, and the rise in neurological illnesses are the primary drivers of the market's expansion. The public's understanding of the significance of preserving brain health and cognitive function throughout life has significantly changed in recent years. Numerous variables, such as increased information availability, an older population, and growing worries about cognitive decline and neurological disorders like Alzheimer's, are to blame for this change.
Market Segments Insights
Type-wise, the Citicoline market is divided into capsules, tablets, powder, eye drops, and injections.
Sports nutrition, personal wellbeing, and treatment are among the applications that form the basis of the market segmentation. Treatment is further divided into categories such as bipolar depression, Alzheimer's illness, stroke, and glaucoma.
The market for Citicoline is segmented by age group, including geriatric, adult, and Pediatric.
The distribution channel, which encompasses both online and offline channels, provides the basis for market segmentation.
Regional Perspectives
In 2022, the biggest market share was held by the North American citicoline market. This is because the North American region's senior population is growing, facial correction and improvement surgeries are becoming more common, and per capita disposable income is considerable.
Due to a robust pharmaceutical and healthcare infrastructure, as well as an aging population throughout the region, the European citicoline market holds the second-largest market share. Furthermore, the Spanish citicoline market is anticipated to develop at the fastest rate in the European region, while the German citicoline market was said to have the greatest market share.
From 2024 to 2032, the Asia-Pacific citicoline market is anticipated to expand at a substantial rate. This is a result of the Asia-Pacific region's growing knowledge of cognitive health and the possible advantages of citicoline supplementation. Furthermore, the Asia-Pacific citicoline market is anticipated to grow at the fastest rate in India, while the China market is predicted to hold the greatest market share.
Africa, Latin America, and the Middle East make up the rest of the world. A increasing senior population and more awareness of cognitive health are expected to fuel growth in the aforementioned regions' citicoline markets.
Companies like Invision Medi Sciences (India), RPG Life Sciences Ltd (India), CHEMO BIOLOGICAL (India), Century Pharma (India), HARBIN PHARMACEUTICAL GROUP (China), UNION KOREA PHARM CO LTD (South Korea), Kyowa Hakko Bio Co., Ltd (Japan), Vitabiotics Ltd (UK), Grupo Ferrer Internacional, S.A (Spain), and Life Extension (US) are just a few examples.